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LNCaP tumor cells, derived from a metastatic lesion of a human prostatic arcinoma, are androgen-sensitive n cell 
culture. Although increase in growth rate is observed with low doses of progestagens or estradiol, these cells contain 
exclusively androgen receptors. In the present study the binding affinity of different ligands for both non-DNA- and 
DNA-binding (transformed) forms of the androgen receptor were analyzed. The cytosolic (non-transformed) form of the 
receptor displayed an abnormal high affinity for progestagens and estradioi when compared with the cytosolic androgen 
receptor from other sources. Subsequently the non-transformed forms of the androgen receptor obtained from LNCaP 
cell nuclei was studied. A high binding affinity was found not only for dihydrotestosterone, but also for progesterone and 
the synthetic progestagen R5020 (relative binding affinity 42% and 10% of dihydrotestosterone). The binding 
characteristics of the transformed androgen receptor were examined in intact cells at 37°C. LNCaP cells were 
compared in this respect with COS cells containing the cloned human androgen receptor, normal human skin fibroblasts 
and PC3 (prostate) and NHIK (cervix) human tumor cell lines. The affinity of the transformed androgen receptors for 
the progestagen R5020 in LNCaP cells was significantly higher than in the other cell systems, although the differences 
were less pronounced than for the non-transformed receptor form. In conclusion: the LNCaP tumor cells contain an 
androgen receptor with an abnormal binding site. This might be due to a mutation and/or  a post-transcriptional effect. 
Introduction 
The actions of steroid hormones on their target cells 
are mediated by specific receptor proteins. The hormone 
binds to the receptor and the receptor is transformed to 
a DNA-binding form with a high affinity for the 
hormone-responsive enhancer elements of the hor- 
mone-responsive g nes. Binding of the transformed re- 
ceptor to these enhancer elements i  an essential step in 
transcriptional ctivation. The specificity of hormonal 
action is accomplished both by the specific recognition 
of the enhancer element by the DNA-binding part of 
the receptor and by the specificty of the hormone-re- 
ceptor interaction, determined by the steroid-binding 
part of the receptor. [1,2]. 
Correspondence: J. Veldscholte, Department of Biochemistry II, 
Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, 
The Netherlands. 
LNCaP tumor cells derived from a metastatic lesion 
of a human prostatic carcinoma contain androgen re- 
ceptors and respond to androgens with growth in cell 
culture [3,4]. In addition, increase in growth rate is 
observed in the presence of low doses of estrogens [3,5] 
and progestagens [6], but these cells do not contain 
progestagen [6] or estrogen receptors [4], as has been 
shown in our laboratory previously with specific anti- 
bodies against hese receptor proteins. Additional proof 
for the absence of progesterone r ceptors was found in 
studies with the synthetic ligand R1881, which has 
equal affinity for both androgen and progestagen recep- 
tors [7]. Specific antibodies against he androgen recep- 
tor complexed with all R1881 bound to receptors, 
thereby demonstrating the absence of RI881 binding to 
progesterone r ceptors [8]. 
Preliminary experiments indicated that the cytosolic 
androgen receptor had a high affinity for both pro- 
gestagens and estrogens. [6]. Cytosolic receptor prepara- 
tions, however, contain only the non-DNA binding 
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form of the receptor and are often exposed to proteo- 
lytic breakdown or are contaminated with other 
steroid-binding proteins as sex-hormone-binding globu- 
lin or lower affinity binders. Therefore, we studied the 
steroid binding specificity of the unoccupied androgen 
receptor in LNCaP cells in intact isolation nuclei at 
4 o C. Because the receptor has to go through a multi-step 
transformation process, before hormone-sensitive g nes 
are activated, the steroid-binding affinity of the nuclear 
transformed receptor was also analyzed in intact cells 
incubated with steroids at the physiological tempera- 
ture. The affinity of the androgen receptor for the 
progestagen R5020 in these cells was compared with the 
affinity of the androgen receptor in three other human 
cell types and with androgen receptors obtained from 
COS cells transfected with androgen receptor cDNA [9]. 
We demonstrate that the androgen receptor of 
LNCaP prostate tumor cells has an unusual high affin- 
ity for several steroids and especially for progestagens. 
Experimental 
Materials 
[3H]R1881 (3H-labeled 17fl-hydroxy-17a-methyl- 
estra-4,9,11-trien-3-one), s.a., 87 Ci/mmol, and un- 
labeled R1881 and R5020 (17a,21-dimethyl-19- 
norpregna-4,9-dione-3,-20-dione) werepurchased from 
New England Nuclear (Boston, U.S.A.). [1,2,6,7-3H] 
Progesterone, s.a., 84 Ci/mmol, was obtained from 
Amersham (U.K.). Triamcinolone acetonide (9a-fluoro- 
llfl-16a,17,21-tetrahydroxy-l,4-pregnadiene-3,20-dione 
16,17-acetonide) was from Sigma (St. Louis, U.S.A.). 
All other steroids were purchased from Steraloids (Wil- 
ton, U.S.A.). 
Buffers. Buffer A: 40 mM Tris-HCl, 1 mM EDTA, 
10% (w/v) glycerol, 10 mM dithiothreitol (DTT), 0.6 
mM phenylmethylsulfonyl fluoride (PMSF) (pH 7.4); 
buffer B: buffer A supplemented with 10 mM molyb- 
date; buffer C: buffer B supplemented with 0.5 mM 
bacitracin and 0.25 mM leupeptin; buffer D: buffer A 
supplemented with 1 mM leupeptin; buffer E: buffer D 
adjusted to pH 8.5, with additionally 0.5 M NaC1; 
buffer F: buffer A supplemented with 0.5 mM bacitra- 
cin; buffer G: buffer F adjusted to pH 8.5, with ad- 
ditionally 0.5 M NaCI; buffer H: buffer A containing 
0.4 M KC1. Homogenization buffer I: prepared in es- 
sence according to Gorski et al. [10]: 10 mM Hepes, 25 
mM NaCl, 0.15 mM spermine, 0.5 mM spermidine, 1
mM EDTA, 2 M sucrose, 0.6 mM PMSF, 10 mM 
dithiotreitol, 10% (w/v) glycerol (pH 7.6); buffer J: 0.5 
M sucrose, further similar to buffer I. 
Cells and tissues 
The LNCaP cell line (derived from a fast-growing 
colony of a lymph node carcinoma of the prostate [3]) 
was a gift from Dr. Horoszewicz (Buffalo, U.S.A.). The 
human prostatic tumor cell line PC3 [11] was kindly 
provided by Dr. van Steenbrugge, Erasmus University 
Rotterdam. Both cell types were cultured in RPMI 1640 
medium (GIBCO) with added penicillin and strepto- 
mycin, supplemented with 7.5% (v/v) heat-inactivated 
fetal calf serum (GIBCO) at 37°C in a humidified 
atmosphere of 5% CO 2 in air. The NHIK  cell line 
(obtained from a human cervix carcinoma [12]) and 
genital skin (preputium) fibroblasts (fibroblasts were 
kindly provided by Dr. Degenhart, Erasmus University 
Rotterdam) were cultured in Eagles minimal essential 
medium (GIBCO) supplemented with 10% (v/v) heat- 
inactivated fetal calf serum (GIBCO) and non-essential 
amino acids (GIBCO). COS-1 cells were grown in 
Dulbecco's modified Eagle's medium (GIBCO) supple- 
mented with 5% fetal calf serum. Further additions,/ 
conditions were as described for LNCaP cells and PC3 
cells. Media were changed every 3 or 4 days and cells 
were passaged once a week by plating out trypsinized 
cell suspensions. Experiments were done with passages 
65-72 (LNCaP), 13-16 (NHIK), 14-16 (fibroblasts) 
and 45-47 (PC3). 
The PC-EW human prostate tumor [13], grown in a 
nude mouse, was kindly provided by Dr. van 
Steenbrugge. The mouse was castrated 4 days before 
death. The tumor was kept on ice and used immediately 
for the competition assay. 
Rat prostates were dissected from adult Wistar rats 
(substrain RP), castrated 24 h before killing. 
Methodology 
Cytosol preparations. LNCaP cells were cultured for 2 
days in 5% dextran-charcoal stripped (stripped) serum. 
After trypsinization and addition of soybean trypsin 
inhibitor the cells were pelleted and homogenized in 
ice-cold buffer B with 15 strokes of a Potter-Elvehjem 
homogenizer at 900 rpm. The cytosol was prepared by 
centrifugation of the homogenate at 105 000 × g for 1 h 
at 2°C. 
Rat prostates from adult Wistar rats (sub-strain RP), 
castrated 24 h before killing, were homogenized at 0 °C 
with a Thurrax homogenizer in buffer B, three times 4 s, 
then centrifuged for 10 min 16 300 × g. The cytosol was 
prepared by centrifugation of the supernatant at 
105000xg fo r l  hat2°C .  
The PC-EW tumor was homogenized in ice-cold 
buffer C by three bursts of 10 s with a Thurrax homo- 
genizer, then centrifuged for 10 min at 16 300 x g. The 
cytosol was prepared by centrifugation of the homo- 
genate at 105000 x g for 1 h at 2°C. The supernatant 
was pre-incubated for 30 rain with 500 nM triamcino- 
lone acetonide (a synthetic glucocorticoid with high 
affinity for the progesterone r ceptor) to occupy possi- 
ble progesterone r ceptors [14,15]. This preparation was 
used for a competition assay. 
Isolation of LNCaP nuclei prior to incubation with 
steroids. Nuclei were isolated from LNCaP cells cul- 
tured for 2 or 3 days in medium without fetal calf serum 
or 5% stripped serum. Cells washed in phosphate- 
buffered saline were harvested by scraping in ice-cold 
homogenization buffer I. The cells were then homoge- 
nized with five strokes in a glass/Teflon homogenizer 
at 1100 rpm. Then half the volume of buffer J was 
added and the suspension was centrifuged for 30 min, 
105000 x g, at 2°C. The pellet was rehomogenized in 
buffer I and half of the volume of buffer J was added. 
The suspension was layered on a buffer I cushion and 
centrifuged for 30 min 105000Xg at 2°C. Pelleted 
nuclei were resuspended in buffer D and used for 
competition assays. 
Scatchard analysis. LNCaP cell cytosol was incubated 
with increasing concentrations (0.5-10 nM) of [3H]- 
R1881 or [3H]progesterone at 4°C for 18 h. In parallel 
incubations 1 /xM of unlabeled R1881 or progesterone 
was included to assess nonspecific binding. Bound and 
free steroids were separated using a dextran-coated 
charcoal assay and Scatchard analysis of the binding 
data was performed [12]. 
Competition assay. The resuspended nuclei were in- 
cubated for 18 h at 4°C with 5 nM [3H]R1881 in the 
presence of unlabeled steroids (R1881, dihydro- 
testosterone, progesterone and R5020 (a synthetic, 
non-metabolizable progestagen)), ranging from 0 to 
100-fold the concentration of the label. Nuclei were 
extracted in buffer E for 1 h at 4 °C and centrifuged for 
30 min at 14 900 x g. Separation of bound and unbound 
steroid was achieved by incubating the extract for 5 min 
with 1 vol. of 20 mM pyridoxal phosphate in 10 mM 
borate buffer (pH 8.1) and precipitating proteins for 10 
min with 10 vol. of protamine sulfate (0.5 mg/ml)  [16]. 
After centrifugation (15 min at 4000 x g) pellets were 
washed, solubilized in soluene (15 rain at 60°C) and 
radioactivity was estimated in 10 ml of the following 
mixture: Instagel (Packard) with 0.1% butylated hy- 
droxytoluene (w/v) and 1% acetic acid (v/v)). 
Competition studies with cytosols were essentially 
performed as described above for nuclear suspensions. 
For LNCaP cell cytosol and rat prostate cytosol the 
dextran-coated charcoal assay was used for separation 
of bound and unbound steroid. 
Affinity labeling of the androgen receptor. LNCaP ceils 
which had been kept on medium containing 5% stripped 
serum for 3 days were incubated with 10 nM [3H]R1881 
with or without 100 nM unlabeled R5020 in serum-free 
medium for 1 h at 37 ° C. In situ photolabeling of the 
receptor was then performed as described by van Laar 
et al. [17]. In brief: after two washes with ice-cold 
phosphate-buffered saline, the culture flasks were put 
on a 300 nm ultraviolet-transilluminator (UVP, U.S.A.) 
and the cells were irradiated for 2 rain. Then nuclei 
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were isolated and extracted as described above. The 
amount of DNA in the pellet was measured to correct 
for the amount of cells in each incubation. 
SDS-PAGE of the affinity-labeled receptor. The 
androgen receptor was precipitated from the extract 
with 10% trichloroacetic acid overnight at 4°C, then 
extensively washed with 10% trichloroacetic acid (3 × ) 
and subsequently with ethyl acetate (3 × ). The precipi- 
tate was dissolved in SDS sample buffer by boiling for 2 
min and SDS-polyacrylamide g l electrophoresis u ing 
8% gels was done according to Laemmli [18]. The slab 
gel was then cut in 2 mm slices. The slices were dis- 
solved in soluene (Packard) for 4 h at 45 °C and radio- 
activity was estimated as described above. Parallel anes 
were run with high-molecular-weight markers (Sigma, 
29 000-200 00). 
Transfection of COS-1 cells. The androgen receptor 
expression plasmid pAR0 was constructed by ligating a 
3037 bp BgllI-PstI cDNA fragment, containing the 
complete androgen receptor protein coding region [9,19], 
in the eukaryotic expression vector pBR328A + [20] 
using standard procedures. 
COS-1 cells were grown in Dulbecco's modified Ea- 
gle's medium supplemented with 5% stripped fetal calf 
serum and antibiotics. Approx. 40% confluent cell cul- 
tures in 10 cm petri dishes were transfected with 10 #g 
pAR0 and 10 #g pTZ carrier plasmid using the calcium 
phosphate precipitation method [21]. 48 h after trans- 
fection, cells were used for the steroid binding assay. 
Competition studies with intact cells. Competition 
studies were performed with LNCaP cells, PC3 cells, 
NHIK  cells, fibroblasts and with COS-cells containing 
the transfected cDNA of the human androgen receptor. 
The cells were kept on 5% stripped serum containing 
medium for 1-3 days and wahsed two times with phos- 
phate-buffered saline prior to the incubations with the 
steroids. The cells were incubated for 1 h at 37 °C with 
10 nM tritiated R1881 with or without 100-fold un- 
labeled R1881 to assess nonspecific binding. R5020 was 
used as a competitor at 10- or 100-fold the molar 
concentration of the labeled R1881. After two washes 
with ice-cold phosphate-buffered saline the cells were 
harvested by scraping in buffer F and centrifugated at 
800 x g. Cell pellets were homogenized by 6 strokes 
with a glass/Teflon homogenizer, followed by 10 rain 
centrifugation (800 × g), 5 min incubation in buffer F 
containing 0.2% (v/v) Triton X-100, 10 min centrifuga- 
tion (800 X g), resuspension in buffer F and a final 
centrifugation step. Pelleted nuclei were extracted in 
buffer G for 1 h at 4 o C. Part of the extract was used for 
protamine sulfate precipitation of the receptor as de- 
scribed under competition assay, part of it was analyzed 
on a 10-30% sucrose gradient in buffer H [22]. 14C- 
labeled bovine serum albumin (4.6 S) and [14C]oval- 
bumin (3.6 S) were used as sedimentation markers. 
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After 20 h 400 000 x g centrifugation at 2 o C the gradi- 
ents were collected in fractions and assayed for radioac- 
tivity. 
After excretion of the nuclei, the pellets were dis- 
solved in 1 M NaOH and used for counting the amount 
of non-extractable [3H]R1881-bound receptors by scin- 
tillation counting. 
DNA measurements DNA content of the extracted 
nuclei was measured according to Hinegardner [23]. 
Results 
Androgen receptor in cytosol fractions 
In preliminary experiments we determined the bind- 
ing characteristics of androgen receptors in the cytosol 
fraction obtained from LNCaP cells for dihydro- 
testosterone, for the synthetic ligand R1881 and for 
progesterone. The binding affinity for dihydro- 
testosterone and for R1881 (K  d 0.4 nM) was higher 
than the affinity for progesterone (K  d 3.9 nM), but the 
number of binding sites was about equal for all three 
ligands. R1881 binds to both androgen and proges- 
terone receptors with equal affinity [14], but immuno- 
logical data showed that progesterone receptors are 
absent in LNCaP cells [6]. The non-metabolizable ligand 
R1881 was therefore preferred as androgen receptor 
ligand in subsequent studies. 
The steroid binding specific of the androgen receptor 
in cytosol obtained from LNCaP cells was compared 
with the specificity of receptors from two other sources: 
rat prostate and the transplantable human prostate 
tumor PC-EW (Table I). In LNCaP cells the affinities 
of the receptor for both progesterone and R5020 (a 
synthetic, non-metabolizable progestagen), are much 
higher then in both PC-EW tumor cells and in rat 
TABLE I 
Relative binding affinities of different steroids for the androgen receptor 
in cytosol fractions of rat prostate, PC-E W cells and LNCaP cells 
Cytosols obtained from rat prostate, PC-EW tumor and LNCaP cells 
were used for competition assays as described in the Experimental 
section. The relative binding affinity (RBA) is expressed in % as the 
ratio of the amounts of non-labeled R1881 and competing steroid 
which are needed for 50% inhibition of binding of tritiated R1881. 
The RBA for R1881 was set at 100% (n.d., not determined). 
Competitor RBA value 
rat PC-EW LNCaP 
prostate cells cells 
R1881 100 100 100 
Dihydrotestosterone 54 83 88 
Testosterone 12 n.d. 25 
R5020 n.d. 0.3 8.4 
Progesterone 0,1 0.3 17 
Estradiol 0,2 n.d. 2.4 
Triamcinolone acetonide < 0A n.d. < 0.1 
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Fig. 1. SDS-polyacrylamide gel electrophoresis profiles of [3 H]R1881 
affinity-labeled nuclear androgen receptor of LNCaP cells labeled at 
37 ° C in the absence (m) and presence ( ) of 10-fold excess of R5020. 
prostate. In addition, the receptor obtained from the 
LNCaP cells showed considerable affinity for estradiol. 
The synthetic glucocorticoid triamcinolone acetonide 
has been used in assays for estimation of androgen 
receptors in the presence of progesterone receptors 
[14,15]. It binds to progesterone receptors but not to 
androgen receptors. The very low affinity of triamcino- 
lone acetonide for the receptor in LNCaP cytosol (Ta- 
ble I) provides additional evidence that no progesterone 
receptors are present. 
Quality of androgen receptor preparations obtained from 
the cell nucleus 
The aim of these studies was to isolate a pure pre- 
paration of intact nuclei containing the receptor in 
ligand-free form and not degraded by proteolytic en- 
zymes (i.e., present in the native 99 kDa form). 
The nuclear preparation obtained by sedimentation 
through a heavy sucrose cushion was free of cyto- 
plasmic contaminants, cellular debris and intact cells, as 
monitored by phase contrast microscopy. The activity 
of the cytoplasmic marker enzyme lactate dehydro- 
genase in these preparations was low (less than 0.2% of 
that of intact cells), indicating that no intact cells were 
present and cytoplasmic ontaminations are minimal. 
The moleculalr size and intactness of the nuclear 
receptor was estimated by SDS-polyacrylamide electro- 
phoresis after photoaffinity labeling of the receptor with 
R1881 (Fig. 1). One major peak is seen in these prepara- 
tions, approximately at the position of 110 kDa, in 
agreement with previous studies [17] which also showed 
this position on SDS gels for the native 99 kDa form [9] 
of the receptor. Proteolytic breakdown of the receptor is 
therefore minimal. 
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Fig. 1 also shows that labeling of receptors in the 
presence of 10-fold excess of the synthetic progestagen 
R5020 results in a decrease of covalently labeled recep- 
tors (77% of control). This decrease in binding of triti- 
ated R1881 to the androgen receptor, in the presence of 
R5020 illustrates the high affinity of the androgen re- 
ceptor for R5020. 
The isolation procedure of nuclei in buffers contain- 
ing spermine and spermidine and a high concentration 
of sucrose, had proven to be useful for the isolation of 
rat liver nuclei, containing tissue specific transcription 
factors [10]. Using this strategy, we found 3000 binding 
sites for R1881 per nucleus; when the cells were kept 
free from ligand prior to the isolation of the nuclei. The 
amount of binding sites for R1881 typically increased to 
20000 sites per nucleus when the cells were prein- 
cubated with ligand. 
Binding specificity of receptors in the isolated nucleus 
LNCaP cells were grown on steroid-depleted medium 
and nucli which contained unoccupied receptors were 
isolated. The results of competition studies for nuclei 
incubated at 4 ° C with R1881, dihydrotestosterone, pro- 
gesterone and R5020 are shown in Fig. 2. At a relatively 
small excess of the competing steroids, the binding of 
labeled R1881 is considerably decreased. The nuclear 
receptor clearly has a high affinity not only for R1881 
and dihydrotestosterone but also for progesterone and 
R5020 (The relative binding affinities for dihydro- 
testosterone, progesterone and R5020 are respectively 
135%, 57% and 13% of the affinity for R1881). 
Excess non-radioactive dihydrotestosterone reduced 
the amount of labeled R1881 bound to the receptors to 
very low values (Fig. 2B), indicating that all R1881 is 
bound to androgen receptors. The glucocorticoid tri- 
amcinolone acetonide (not shown) did not compete for 
the nuclear binding sites, in agreement with the results 
obtained with cytosolic receptor preparations described 
above. 
The steroid binding specificity of the transformed andro- 
gen receptor in different cell types 
In the next series of experiments, the binding 
specificity of the transformed (DNA-binding form) 
androgen receptor was estimated in intact cells which 
were incubated for 1 h at 37 °C with different steroids. 
Two different non-metabolizable ligands were used for 
comparison of the binding specificity: the progestagen 
R5020 and the androgen receptor ligand R1881. For 
this study receptors in LNCaP cells were compared with 
receptors in the human tumor PC3 and NHIK  cells, in 
normal human fibroblasts, and in COS cells in which 
the human androgen receptor cDNA was expressed. 
These cells do not contain progesterone receptors 
[11,12,24]. 
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Fig. 2. Compet i t ive b inding curves of different steroids for the non- 
occupied androgen receptor in intact isolated nuclei from LNCaP 
cells at 4°C .  The given values are means±S.D,  of three separate 
experiments. The curve for R1881 (dotted line) is shown in all four 
panels. (A) R1881 (e); (B) d ihydrotestosterone (o ) ;  (C) progesterone 
( - ) ;  (D) R5020 (v). 
Fig. 3 shows the amounts of [3H]R1881 in nuclear 
extracts obtained from the different cells, incubated in 
the presence of competing R5020. In the presence of a 
100-fold molar excess of unlabeled R5020, the labeling 
of the receptors was significantly lower for LNCaP cells 
than for the other cells: 0.01 > P> 0.002 (Student's 
t-test), when compared with NHIK  cells, and p < 0.001 
when compared with the other cells. We also observed 
some variation in receptor labeling for the other cells. 
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Only between the fibroblasts and the COS cells this was 
just significant (0.05 > P > 0.02). 
In Fig. 4 the results of sucrose density gradient 
centrifugation of the labeled nuclear extracts for LNCaP 
and NHIK  ceils are shown. The amount of label re- 
covered from the peak fractions of the gradients, was 
identical to the amount of label found after protamine 
sulfate precipitation of the nuclear extracts. This indi- 
cates that all receptors present in the extracts are pre- 
cipitated in the protamine sulfate assay. 
The amount of label extracted from the nuclei varied 
between 41% and 73% for the different cells. For the 
residual, non-extracted receptors, the results of the com- 
petition studies were similar to those presented in Fig. 
3. The low amount of [3H]R1881 extracted from LNCaP 
cell nuclei, in the presence of R5020, as observed above, 
is therefore not due to an R5020-dependent change in 
extraction efficiency of the binding sites in the nuclear 
fraction. In fact, the sum of extractable and non-extrac- 
table values gave results similar to those presented in 
Fig. 3. 
Discussion 
The results in the present study show that the 
androgen receptor of the prostatic ell line LNCaP has 
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Fig. 3. Competition of the progestagen R5020 for androgen receptor 
binding sites in different cell types. Intact umor cells (LNCaP, NHIK 
and PC3), normal human skin fibroblasts and COS cells transfected 
with the human androgen receptor were incubated at 37°C with 
[3H]R1881 and a 10- or 100-fold molar excess of unlabeled R5020. 
Receptors were extracted from the nuclei as described in the Experi- 
mental section. The amount of specific [3H]R1881 binding/mg DNA 
in the absence ofcompetitor (R5020) was set at 100%. The values are 
means+ S.E. of three (NHIK, PC3, COS cells and fibroblasts) orfour 
(LNCaP cells) separate experiments. 
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Fig. 4. Sucrose density-gradient centrifugation f androgen receptors 
extracted from nuclei of LNCaP and NHIK cells. Nuclei were iso- 
lated and extracted from cells incubated with 10 nM [3H]R1881 alone 
(A), or in the presence of100-fold unlabeled R1881 (zx), 10-fold R5020 
(o) or 100-fold R5020 (O). 
a broad specificity. In addition to androgens, especially 
progestagens are bound with high affinity. The results 
also show that the progestagen binding capacity of the 
LNCaP cells was not due to the presence of proges- 
terone receptors. This observation is in agreement with 
immunological data from previous tudies which showed 
that progesterone r ceptors are absent [6] and that only 
androgen receptors are present in LNCaP cells [8]. 
The binding affinity of the androgen receptor in 
LNCaP cells was studied with two synthetic non- 
metabolizable igands: R1881, a steroid with equal af- 
finity for androgen receptors and progesterone r cep- 
tors [14] and generally used in androgen receptor bind- 
ing studies [25], and R5020, a progestagen with a very 
low affinity for androgen receptors [26]. Receptors were 
labeled at 4 °C to study the untransformed (non-DNA- 
binding) form of the receptor and at 37 °C to study the 
transformed (DNA-binding) form of the receptor. 
The results obtained with the cytosolic fractions of 
LNCaP cells, rat prostate and PC-EW tumor cells 
strongly indicate that the binding specifity of the 
androgen receptor in LNCaP cells is abnormal. In fur- 
ther studies the receptors were isolated from purified 
nuclei to exclude an unusual binding specificity either 
TABLE II 
Relatioe binding affinities of different steroids for the androgen receptor 
in different sources: Literature data 
Relative binding affinities (RBA) of some steroids for the androgen 
receptor in different cell types, calculated as described in the legend of 
Table I (n.d.: not determined). Data were obtained from: 
(1) Asselin et al., hypertrophic human prostate cytosol, incubated at 
0 -4  ° C [14]. 
(2) Asselin et al., rat ventral prostate cytosol, incubated at 0 -4  °C  [7]. 
(3) Bergink et al., human breast cancer cells MCF-7 cytosol, in- 
cubated at 4°C  [39]. 
(4) Bergink et al., MCF-7 cells, whole cell assay, incubated at 37 °C  
[39]. 
(5) Brown et al., human genital skin fibroblasts, whole cell assay, 
incubated at 37 °C  [24]. 
Competitor RBA value 
Data from: 1 2 3 4 5 
R1881 100 100 100 100 100 
Dihydrotestosterone 42 61 100 89 54 
Testosterone 9 36 33 34 n.d. 
Progesterone 2 < 1 5 0.5 0.6 
R5020 <1 <1 n.d. n.d. n.d. 
Estradiol < 1 < 1 n.d. n.d. 0.8 
Triamcinolone acetonide < 1 n.d. n.d. n.d. 0.3 
due to contaminations of the cytosol with low-affinity 
binding proteins or to formation of proteolytic frag- 
ments of the receptor. Low-affinity binders for estro- 
gens and other steroids have previously been de- 
termined in several tissues [27]. Rapid breakdown of 
androgen receptors has been shown for receptors in 
prostate tissue [28] and an effect in steroid binding can 
not be excluded. The androgen receptors which were 
obtained from the purified nuclei were intact. The 
photoaffinity-labeled r ceptor migrated as an 110 kDa 
protein on SDS-PAGE as was found for the native 99 
kDa receptor [9,17]. 
The non-transformed (non-DNA-binding) receptor 
in the purified nuclear fraction showed affnities for 
progesterone and the progestagen R5020 (42% and 10%, 
respectively, of dihydrotestosterone) which are ex- 
tremely high for an androgen receptor compared to 
observations in other studies, see Table II. 
The binding characteristics of the transformed, 
DNA-binding form of the androgen receptor was ex- 
amined in intact cells at 37°C. LNCaP cells were 
compared in this respect with COS cells containing the 
cloned human anhydrogen receptor, normal human skin 
fibroblasts and PC3 (prostate) and NHIK (cervix) hu- 
man tumor cell lines. The affinity of the transformed 
androgen receptors for the progestagen R5020 in LNCaP 
cells was significantly higher than in the other cell 
systems, although the differences were less pronounced 
than for the non-transformed receptor form. This dif- 
ference in affinity between transformed and non-trans- 
formed receptors might be due to a modulation of 
193 
affinity of the receptor for steroids during the transfor- 
mation process. Weichman and Notides [29] showed 
differences in ligand-receptor dissociation rates for the 
estrogen receptor in the transformed and untransformed 
form, and observed that the ratios of the dissociation 
rates for different steroids were not identical for these 
receptor forms. This might result in different affinity 
constants and relative binding affinities for a series of 
steroids depending on whether or not the assay condi- 
tions allow transformation of the receptor. Effects of 
assay conditions on steroid binding affinities, have been 
observed by Raynaud et al. [30] who showed ifferences 
in relative binding affinity of several steroids for differ- 
ent receptors depending on incubation time or temper- 
ature of the assay. A temperature-dependent change in 
affinity for estradiol was also shown for the human 
estrogen receptor containing an artefactual point muta- 
tion in the hormone-binding domain [31]. 
In the present study we used a mild procedure for 
isolation of nuclei [10] to prevent unoccupied androgen 
receptors from leaking out of the nucleus during isola- 
tion. The nuclei isolated from steroid-depleted cells, 
however, contained only 15% of the number of recep- 
tors found in the nuclei after incubation of the cells 
with androgens. Two explanations for this results are 
possible: either the unoccupied receptors do not reside 
in the nucleus, or the isolation procedure does not 
prevent leakage of androgen receptors out of the nucleus. 
Histochemical studies with specific antibodies against 
the androgen receptor are needed to obtain a definite 
answer about the localization of the unoccupied recep- 
tor. For estrogen and progestagen receptors a predomi- 
nant nuclear localization was observed [32,33], but un- 
occupied glucocorticoid receptors are also present in the 
cytoplasmic compartment [34,35]. 
Studies of cell systems containing androgen receptors 
with altered steroid specificity are scarce. Brown et al. 
[36] studied a mutant androgen receptor in human 
fibroblasts of certain patients with the androgen in- 
sensitivity syndrome and observed increased binding of 
progestagens. However, in contrast o our studies with 
LNCaP cells, also a decrease in affinity for androgens 
was found. Recently it was reported that the androgen 
receptor in these cells contained a mutation in the 
steroid binding domain, which resulted in replacement 
of valine in the normal sequence with a methionine in 
the mutated androgen receptor gene [37]. The changed 
binding pattern of the LNCaP-cell androgen receptor 
could be due to a mutation in the steroid binding 
domain, although it might also be envisaged that post- 
transcriptional processing of the receptor is changed in 
the tumor cell (e.g., by phosphorylation). 
If an abnormal binding pattern of steroids to a 
receptor is found, ligands that normally do not bind 
and transform the receptor, might lead to enhanced 
transcription of specific genes, but only when all subse- 
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quent steps towards gene activation are effectuated in a 
comparable way as by the natural ligand. The growth 
effects on LNCaP ceils of progestagens described by 
Schuurmans et al. [6] indicate that some progestagens 
indeed have the capacity to transform the receptor and 
subsequently induce growth stimulatory effects. In ad- 
dition, it has been recently shown that LNCaP cells 
behave aberrantly with respect o the response to anti- 
androgens. Both Wilding et al. [38] and studies in our 
laboratory (unpublished observations) howed increase 
in growth rate and excretion of prostate specific acid 
phospatase with different anti-androgens (cyproterone 
acetate and flutamide derivatives). It is tempting to 
speculate that there is a relationship between the 
abnormal steroid-binding specificity of the androgen 
receptors and the androgenic actions of progestagens 
and anti-androgens in LNCaP cells. 
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